India’s leading cancer care provider, HealthCare Global Enterprises (HCG), has unveiled a research initiative in partnership with the innovative startup, Trucan Diagnostics Pvt Ltd, known for its cutting-edge cancer diagnostics. The goal of this collaboration is to authenticate a range of pioneering diagnostic tests that enhance the precision of detecting primary and recurrent/metastatic cancer, predict responses to therapies, and oversee treatment effectiveness.
Through this alliance, HCG and Trucan are set to jointly undertake comprehensive validation trials on Trucan’s newly-developed cancer diagnostic tests. Leveraging advanced methodologies like next-generation sequencing and innovative biomarker-driven diagnostics, these tests aim to deliver accurate detection of primary, recurrent/metastatic cancers, forecast treatment response before therapy, and track patient progress during chemotherapy or targeted treatments. The data gleaned from these validations will be pivotal in ratifying their clinical value, potentially setting the stage for their seamless incorporation into standard clinical practice.
Trucan’s groundbreaking biomarker-driven cancer detection techniques promise a substantial upgrade over existing procedures. By offering precise predictions on therapy responses, these diagnostics intend to enable oncologists to tailor treatment plans better, decrease ineffective treatments, and reduce related complications while also cutting overall treatment expenses.
Dr. B S Ajaikumar, Executive Chairman at Healthcare Global Enterprises Limited, remarked, “Our relentless goal is to lead with innovation and empathy, especially in battling cancer. This synergy with Trucan Diagnostics marks a crucial leap in bolstering India’s prowess in precision oncology. By endorsing next-generation diagnostic instruments crafted in Triesta Sciences’ Genomics lab, we aspire not only to enhance detection but also to provide highly customized treatment plans that cater to each patient’s unique cancer path. These advancements resonating with our vision are geared towards making state-of-the-art, impactful cancer treatment more widely accessible, thereby augmenting survival rates and life quality nationwide.”
Similarly, Dr. Raman Govindarajan, Founder & CEO of Trucan Diagnostics, expressed, “Aligning with HCG offers a significant chance to authenticate our innovative diagnostic solutions practically. The collaborative outcomes are poised to substantially influence our dedication to progressing precision oncology, optimizing patient care, and elevating cancer patient outcomes.”
This research cooperation underscores HCG and Trucan’s unwavering dedication to revolutionizing oncology diagnostics and establishing a robust evidence base for emerging technologies. Utilizing their collective knowledge, these organizations strive to generate meaningful insights that could significantly advance cancer care and patient results.